Benjamin Garmezy, MD, discusses challenges associated with navigating the current frontline armamentarium in both clear cell and variant RCC, the impact of frontline IO doublets and IO/TKI regimens on patient outcomes, and the importance of ongoing combination studies for patients with variant RCC.
Read More
Ongoing ADC Development Continues to Gain Traction in Ovarian Cancer
January 24th 2024Sarah Crafton, MD, discusses the ongoing development of agents targeting key biomarkers in ovarian cancer, such as FRα and HER2; expands on the integration of mirvetuximab soravtansine into clinical practice and its investigation in earlier lines; and emphasizes the importance of continued patient enrollment onto ongoing or planned ADC trials in ovarian cancer.
Read More
Grivas Expands on Key Data From the 2023 ESMO Congress in Urothelial Cancer
January 23rd 2024Petros Grivas, MD, PhD, spotlights key advancements and research in urothelial cancer reported at the 2023 ESMO Congress, detailing findings from the phase 3 CheckMate 901, EV-302/KEYNOTE-A39, and THOR trials.
Read More
Practical Toxicity Management Awareness With FGFR Inhibitors Improves Real-World Patient Outcomes
January 8th 2024Vivek Subbiah, MD, emphasizes the need for improved guidance on practical toxicity management for various FGFR-altered malignancies, highlights best practices for monitoring and managing the most common on-target toxicities associated with FGFR inhibitors, and discusses the key implications of this review for those utilizing FGFR inhibitors.
Read More
Optimal Personalization of Therapy In TNBC Necessitates Consistent Biomarker Identification
January 7th 2024Pooja Advani, MBBS, MD, details the encouraging activity of antibody-drug conjugates in triple-negative breast cancer, the importance of utilizing next-generation sequencing to inform treatment selection after progression on CDK4/6 inhibitors in this disease setting, and more.
Read More
Lifileucel Demonstrates Long-Term Efficacy and Survival Benefit in Advanced, Pretreated Melanoma
January 5th 2024Lifileucel demonstrated clinically meaningful antitumor activity alongside early, durable responses in patients with advanced melanoma following progression on checkpoint inhibitors.
Read More
Lenvatinib Plus Pembrolizumab Fails to Improve OS and PFS Over Docetaxel in Stage IV NSCLC
January 4th 2024Lenvatinib plus pembrolizumab did not provide a survival advantage vs standard-of-care docetaxel in patients with advanced-stage non–small cell lung cancer who experienced disease progression following prior exposure to a PD-L1 inhibitor and platinum-based chemotherapy.
Read More
Advani Spotlights Clinical Trial Implications Across Breast Cancer Subtypes
January 4th 2024Pooja Advani, MBBS, MD, details key advancements and the significance of pivotal trials that were presented by her colleagues at a recent OncLive® State of the Science Summit™ on breast cancer, which she chaired.
Read More
Pirtobrutinib Approval Adds Effective Third-Line Option to Previously Treated CLL/SLL Armamentarium
January 3rd 2024Lori A. Leslie, MD, discusses the significance of the FDA approval of pirtobrutinib for this population alongside the unmet needs it may address, highlights the efficacy and notable toxicities seen with the agent in the BRUIN study, and expands on the continued investigation of pirtobrutinib vs other standard-of-care regimens in various CLL subtypes.
Read More
Sara M. Tolaney, MD, MPH, discusses the significance of the FDA approval of capivasertib and fulvestrant in this patient population, highlights the efficacy and notable toxicities seen in the CAPItello-291 trial, and touches on key considerations when selecting between this and other standard regimens following CDK4/6 inhibitor progression.
Read More
Obinutuzumab Use Decreases Incidence of Steroid-Requiring cGVHD After Transplant
December 21st 2023Utilizing obinutuzumab to enhance B-cell depletion significantly reduced the need for corticosteroids and increased relapse-free survival in patients with steroid-requiring chronic graft-vs-host disease undergoing well-matched hematopoietic stem cell transplant.
Read More
NCCN Adds 2 Category 1 Recommendations for Amivantamab in NSCLC Clinical Practice Guidelines
December 21st 2023The National Comprehensive Cancer Network has updated its Clinical Practice Guidelines for Non–Small Cell Lung Cancer for 2024 to include 2 new category 1 recommendations for amivantamab alongside chemotherapy in patients with treatment-naive, EGFR-mutated advanced NSCLC.
Read More
Non–Clear Cell RCC Subtypes Require Individualized Approach to Treatment Selection
December 19th 2023Jaime R. Merchán, MD, spotlights case studies of patients with rare non-ccRCC histologies, discussing their clinical presentation, recent data on immunotherapy and targeted treatment options for the management of these disease subtypes, and patient outcomes on these therapies.
Read More
Exploratory Analyses of KATHERINE Trial Inform Adjuvant T-DM1 Use in HER2+ Breast Cancer
December 18th 2023Maria Hafez, MD, spotlights the KATHERINE trial in HER2-positive breast cancer, expanding on the respective toxicity profiles of T-DM1 and trastuzumab that were identified in an exploratory safety analysis of the trial; updated outcomes with T-DM1 in those with residual invasive disease after neoadjuvant treatment and surgery; and more.
Read More
Repotrectinib May Serve as a New Standard of Care Across Treatment Lines in ROS1+ NSCLC
December 17th 2023Alexander Drilon, MD, highlights how the approval of repotrectinib addresses the need for improved therapies for patients who have progressed on a previous TKI and delves into notable neurologic toxicities seen with the agent.
Read More
Oral CELMoD Mezigdomide May Address Logistical Challenges Linked With R/R Myeloma Management
December 15th 2023Paul G. Richardson, MD, shares clinical findings and several case studies showcasing the encouraging activity and safety of mezigdomide in patients with relapsed/refractory multiple myeloma.
Read More